Foamix Pharmaceuticals Ltd Banner Image

Foamix Pharmaceuticals Ltd

  • Ticker FOMX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Foamix Pharmaceuticals Ltd Logo Image
  • 11-50 Employees
  • Based in Rehovot, Israel
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for the treatment of acne, impetigo, and other skin conditions in the United States, Germany, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation which has completed a dose-ranging Phase II clinical trial for the treatmentMore of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus.
4.8 / 5.0 (176)

Foamix Pharmaceuticals Ltd reports have an aggregate usefulness score of 4.8 based on 176 reviews.

Foamix Pharmaceuticals Ltd

Most Recent Annual Report

Foamix Pharmaceuticals Ltd
MOST RECENT 2019 Form 10K, 2018 Annual Report

Report Locked. Foamix Pharmaceuticals Ltd has reached its limit for free report views.

Foamix Pharmaceuticals Ltd does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Foamix Pharmaceuticals Ltd Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!